From screening to surveillance, Oncotype DX Breast Recurrence Score broadens Exact Sciences’ cancer toolkit

Exact Sciences is pushing deeper into personalized oncology with its Oncotype DX Breast Recurrence Score test, a genomic assay used to guide adjuvant therapy decisions in early-stage breast cancer. The test is gaining traction as clinicians look to tailor chemotherapy more precisely.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 7:47 AM ET. Details in the imprint.

Exact Sciences has been known to most US consumers for Cologuard, its stool-based colorectal cancer screening kit, but in oncology clinics another product from the Madison-based company is increasingly central to treatment decisions: the Oncotype DX Breast Recurrence Score test, a genomic assay that analyzes the expression of 21 genes in tumor tissue to estimate the risk of distant recurrence and the likely benefit from adjuvant chemotherapy in certain early-stage breast cancer patients. The official product information describes the assay as a 21-gene test for patients with estrogen receptor-positive, HER2-negative, early-stage breast cancer. It is ordered by oncologists rather than consumers and plays a role in one of the most delicate choices in breast cancer care: whether to add chemotherapy after surgery and endocrine therapy.

How the Oncotype DX Breast Recurrence Score test works in practice

Oncotype DX Breast Recurrence Score falls into the category of multigene expression assays, but Exact Sciences has tried to make the workflow relatively straightforward for clinics: the test is performed on formalin-fixed, paraffin-embedded tumor tissue, usually from the original surgical specimen or biopsy, which is sent to a centralized Exact Sciences laboratory, where quantitative RT-PCR is used to measure the expression of 21 genes (16 cancer-related and 5 reference genes) to generate a Recurrence Score from 0 to 100. That score is then translated into risk categories and estimated chemotherapy benefit, with reporting tailored to menopausal status and nodal involvement based on validation studies. According to the company, turnaround time is generally around two weeks from receipt of the tumor sample, allowing results to be integrated into the adjuvant treatment planning window without major delays.

The clinical influence of the test rests largely on high-profile trials such as TAILORx and RxPONDER, which showed that many women with hormone receptor-positive, HER2-negative, node-negative or limited node-positive breast cancer and intermediate Recurrence Scores can safely omit chemotherapy without compromising invasive disease-free survival, while those with higher scores derive clear benefit from cytotoxic treatment. Professional guidelines have progressively woven the assay into recommendations: in the United States, the National Comprehensive Cancer Network (NCCN) lists the Oncotype DX Breast Recurrence Score as an option to help guide adjuvant chemotherapy decisions in specific early-stage breast cancer populations, and several European societies have provided similar language in their guidance. Payers have followed suit, and Medicare in particular has long provided coverage for appropriate use, which has helped embed the test in routine U.S. oncology practice.

From a commercial standpoint, Oncotype DX Breast Recurrence Score sits in Exact Sciences’ precision oncology portfolio alongside other tumor profiling products and minimal residual disease offerings, complementing Cologuard rather than competing with it; whereas Cologuard is aimed at average-risk individuals for colorectal cancer screening, the breast assay is used after a cancer diagnosis and is ordered by physicians at specialty centers and community oncology practices. The company emphasizes that the test is not designed to replace standard clinicopathologic factors such as tumor size, grade or nodal status, but to refine them with genomic information that can spare some patients from unnecessary chemotherapy and its long-term toxicities while still flagging those who stand to benefit. As health systems place greater weight on value-based care and quality-of-life outcomes, the ability to avoid overtreatment without sacrificing efficacy is central to the product’s positioning.

Beyond the United States, the Oncotype DX Breast Recurrence Score test is also offered in multiple international markets through partnerships and Exact Sciences’ own commercial footprint, with reimbursement decisions varying country by country and often following local health technology assessments and clinical guideline updates. A recent example comes from the United Kingdom, where the National Institute for Health and Care Excellence (NICE) has acknowledged the use of multigene tests such as Oncotype DX to help inform decisions about adjuvant chemotherapy in certain early breast cancer cases, provided that local cost-effectiveness criteria are met. Hospitals in Canada, parts of Europe and selected Asia-Pacific markets have also incorporated the test into care pathways, typically for estrogen receptor-positive, HER2-negative tumors, though the extent of coverage and patient access remains uneven and subject to ongoing negotiations between healthcare payers and the manufacturer.

Within Exact Sciences’ overall strategy, precision oncology tests like Oncotype DX Breast Recurrence Score are designed to diversify revenue beyond screening, smooth out the cyclicality of colorectal cancer testing volumes and deepen relationships with oncologists who may use multiple products from the portfolio across a patient’s cancer journey. That context matters for investors watching the company’s financials: the precision oncology segment, which includes Oncotype DX, generated roughly one-third of Exact Sciences’ total revenue in recent reporting periods, according to company filings and earnings presentations. Industry coverage has highlighted management’s efforts to balance the screening and precision oncology franchises as payers, clinicians and patients seek more personalized cancer care. Shares of Exact Sciences (US30063P1057) traded on NASDAQ at about $41 in mid-June 2026.

Oncotype DX Breast Recurrence Score at a glance

• Product: Oncotype DX Breast Recurrence Score test
• Manufacturer: Exact Sciences Corporation
• Category: New Release/Launch - precision oncology diagnostic
• Launch date: Initially introduced in the mid-2000s, with ongoing updates and clinical validation
• MSRP / Price: Not publicly listed; pricing varies by market and payer contracts
• Availability: Ordered by oncologists, processed at Exact Sciences laboratories, with coverage by Medicare and many commercial insurers in the U.S.; also available in select international markets
• Target audience: Patients with estrogen receptor-positive, HER2-negative, early-stage breast cancer, particularly those with node-negative or limited node-positive disease
• Key differentiator / USP: 21-gene expression assay providing a quantitative Recurrence Score used to estimate distant recurrence risk and chemotherapy benefit, supported by large prospective clinical trials

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.